NCT00002097已完成1 期
A Phase I/II Clinical Study of Nystatin I.V. (Intravenous) in Patients With HIV Infection.
Argus Pharmaceuticals1 个研究点 分布在 1 个国家开始时间: 2001年8月31日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 试验地点
- 1
研究概览
简要总结
To evaluate the clinical toxicity, safety, and maximum tolerated dose (MTD) of intravenous nystatin in patients with HIV infection. To evaluate the potential anti-HIV activity and clinical pharmacology of intravenous nystatin.
详细描述
Cohorts of three patients each are treated at escalating doses of intravenous nystatin, administered every other day, until the MTD is reached. Each cohort is observed for toxicity for at least 2 weeks before escalation in subsequent patient cohorts is initiated.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Concurrent Medication:
- •Aerosolized pentamidine (300 mg once a month) for PCP prophylaxis in patients with CD4 count <= 200 cells/mm
- •(Patients with CD4 count > 200 cells/mm3 who are already on aerosolized pentamidine may continue such therapy at the discretion of the investigator.)
- •Prophylaxis against Mycobacterium avium Complex in patients with CD4 count <= 100 cells/mm
- •Concurrent Treatment:
- •Local treatment for Kaposi's sarcoma lesions with less than 25 percent increase in measurable disease.
- •Patients must have:
- •HIV antibody positivity.
- •Absolute CD4 count < 500 cells/mm3 on two determinations within 15 days prior to study entry.
- •At least 6 months of prior zidovudine (AZT) therapy.
- •No active opportunistic infection requiring ongoing therapy.
- •Normal neurologic status by standard assessment.
- •Life expectancy of at least 6 months.
排除标准
- •Co-existing Condition:
- •Patients with the following symptoms and conditions are excluded:
- •Neoplasm other than basal cell carcinoma of the skin or stable untreated HIV-related Kaposi's sarcoma (provided there is no progression in the Kaposi's sarcoma beyond 25 percent of measurable disease).
- •Clinically significant cardiac disease.
- •Known hypersensitivity to polyene antibiotics.
- •Patients with the following prior conditions are excluded:
- •History of myocardial infarction or arrhythmias.
- •Prior Medication:
- •Excluded within 2 weeks prior to study entry:
- •Antiretroviral agents or interferons.
- •Biological response modifiers.
- •Corticosteroids.
- •Cytotoxic chemotherapeutic agents.
- •Drugs that can cause neutropenia or significant nephrotoxicity.
- •Rifampin or rifampin derivatives.
- •Systemic anti-infectives.
- •Prior Treatment:
- •Excluded within 2 weeks prior to study entry:
- •Radiation therapy. Active drug or alcohol abuse.
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Pharmacokinetics of Nystatin LF I.V. in Patients With Acquired Immune Deficiency Syndrome-Related Complex (ARC)HIV InfectionsNCT00001998Argus Pharmaceuticals
已完成
1 期
A Study of Nystatin in HIV-Infected PatientsHIV InfectionsNCT00002313Argus Pharmaceuticals
终止
2 期
YN001-004 in Patients With Coronary Atherosclerosis in AustraliaCoronary Artery DiseaseCoronary Atherosclerotic DiseaseNCT06700720Beijing Inno Medicine Co., Ltd.3
终止
1 期
A Safety Study of SYNT001 in Participants With Warm Autoimmune Hemolytic Anemia (WAIHA)Warm Autoimmune Hemolytic AnemiaNCT03075878Alexion Pharmaceuticals, Inc.8
已完成
1 期
Clinical Study of YS110 in Patients With Malignant Pleural MesotheliomaMalignant Pleural MesotheliomaNCT03177668Kissei Pharmaceutical Co., Ltd.40